Reprogramming T Cells to Induced Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) are cumbersome and inconvenient, particularly when sourcing from human somatic cells, as they require invasive procedures and labor-intensive cell culture systems, and there is a lack of reports on producing iPSCs from clinically accessible sources like T cells or hematopoietic progenitor cells from blood samples.
Innovation Solution
The development of methods to derive iPSCs from T cells and/or hematopoietic progenitor cells using reprogramming factors such as Sox and Oct proteins, introduced through expression cassettes in a polycistronic transcription unit, allowing for the generation of iPSCs from small volumes of blood samples, including refrigerated or cryopreserved samples, without the need for mobilizing hematopoietic progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iPSCs are generated from dermal fibroblasts using traditional methods, then pluripotent stem cells can be obtained, but the process requires invasive skin biopsies and labor-intensive cell culture expansion
Solution Approach 1:
The patent extracts the reprogramming capability from traditional fibroblast sources and applies it to blood-derived cells. By using expression cassettes containing reprogramming factors (Oct4, Sox2, Klf4, c-Myc) that can be introduced into T cells and hematopoietic progenitor cells directly from blood samples, the method eliminates the need for invasive skin biopsies while maintaining the ability to generate iPSCs
Solution Approach 2:
The patent changes the cell source parameter from dermal fibroblasts to blood-derived cells (T cells and hematopoietic progenitor cells). This parameter change transforms the accessibility of the cell source from requiring invasive procedures to using simple blood draws, while the reprogramming factors enable the blood-derived cells to acquire pluripotent characteristics
2Adaptability or versatility
If somatic cells are obtained directly from human subjects, then patient-specific stem cells can be generated, but the process requires invasive procedures and maintenance in labor-intensive cell culture systems
Solution Approach 1:
The patent uses expression cassettes as templates to copy reprogramming factors into the target blood-derived cells. These expression cassettes contain the necessary genetic instructions (Oct4, Sox2, Klf4, c-Myc genes) that when introduced, cause the blood cells to copy the pluripotent state, eliminating the need for complex long-term culture maintenance while preserving patient-specific genetic information
Solution Approach 2:
The patent performs preliminary action by preparing expression cassettes with reprogramming factors before introducing them into blood-derived cells. This preliminary preparation of reprogramming tools allows the blood cells to be directly reprogrammed without requiring extensive prior culture expansion or complex system setup, simplifying the overall process while maintaining patient-specific customization
3Ease of operation
If blood samples are used as a source for iPSC generation, then clinically accessible cell sources can be utilized, but there was no established method for reprogramming T cells or hematopoietic progenitor cells
Solution Approach 1:
The patent introduces expression cassettes as intermediaries that mediate the transfer of reprogramming factors into blood-derived cells. These expression cassettes serve as the bridging mechanism that enables reliable reprogramming of T cells and hematopoietic progenitor cells from blood samples, transforming an previously unproven approach into a reliable method for generating iPSCs from clinically accessible sources
Data Source
AI summary
Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34.sup.+ hematopoietic cells, such as human CD34.sup.+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.